Rapid Communication
Copyright ©2007 Baishideng Publishing Group Co.
World J Gastroenterol. May 21, 2007; 13(19): 2733-2737
Published online May 21, 2007. doi: 10.3748/wjg.v13.i19.2733
Table 1 Demographic features and baseline biochemical, prognostic indices in study and control groups
Study group(n = 15)Control group(n = 15)P
Mean age (SD)47.3 (16.8)44.9 (11.2)NS
Sex (Male:Female)6:98:7NS
Body mass index mean (SD)24.7 (7.8)27.1 (9.5)NS
Interval between onset of symptoms and admission (days) median (range)2 (1-9)1 (1-6)NS
Etiology (n, %)
Biliary11 (73.3)12 (80)NS
Post-ERCP2 (13.3)2 (13.3)NS
Hyperlipidemia1 (6.6)1 (6.6)NS
Idiopathic1 (6.6)0 (0)NS
At admission
Serum amylase, mean (SD) IU/L545 (232)498 (277)NS
Serum lipase, mean (SD) IU/L554 (167)396 (187)NS
Serum CRP, mean (SD) mg/L232 (97)244 (104)NS
Serum prealbumin, mean (SD) mg/L17.6 (4.5)19.1 (6.7)NS
APACHE II score, mean (SD)9.4 (3.7)9.6 (3.8)NS
Balthazar CT score, mean (SD)8.5 (4.6)9.1 (5.2)NS
Table 2 Clinical course of patients in the study and control groups
Study groupControl groupP
Median duration of hospital stay ± (range)10 ± 4 (8-14)15 ± 6 (7-26)< 0.05
Median value of days in ICU ± (range)6 ± 2 (5-8)6 ± 2 (5-7)NS
Median duration of EN ± (range)8 ± 4 (6-12)10 ± 4 (6-13)NS
Median duration (days) of serum amylase or lipase normalization ± (range)7 ± 2 (6-9)8 ± 3 (6-11)NS
Complications
Multiorgan failure (n)12
Cholangitis (n)10
Sepsis (n)12
Pseudocyst (n)21
Number of deaths (n)24
Overall complications (%)7/15 (46.6)9/15 (60%)< 0.05
Table 3 Time (days) for normalization of CRP, APACHE II and CT scores in the study and control groups, (mean ± SD)1
ItemsStudy groupControl groupP
CRP mg/L7 ± 2  10 ± 3< 0.05
APACHE II score4 ± 26.5 ± 3< 0.05
CT score12 ± 4  16 ± 3< 0.05